Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
69.68
-4.09 (-5.54%)
Jun 23, 2025, 3:10 PM - Market open
Novo Nordisk Revenue
Novo Nordisk had revenue of 78.09B DKK in the quarter ending March 31, 2025, with 19.49% growth. This brings the company's revenue in the last twelve months to 303.14B, up 24.11% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
303.14B DKK
Revenue Growth
+24.11%
P/S Ratio
7.43
Revenue / Employee
3,919,133 DKK
Employees
77,349
Market Cap
326.28B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Thermo Fisher Scientific | 42.90B |
NVO News
- 34 minutes ago - Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities - GlobeNewsWire
- 2 hours ago - Novo Nordisk Ends Partnership with Hims & Hers - WSJ
- 5 hours ago - Hims & Hers' stock plunges. Here's why Wegovy parent ended its partnership with the company. - Market Watch
- 6 hours ago - Novo Nordisk's Weight Loss Injection CagriSema Data Sparks Investor Concern - Benzinga
- 6 hours ago - Hims & Hers Stock Plunges as Novo Nordisk Abruptly Ends Partnership - Barrons
- 6 hours ago - Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 20% - CNBC
- 7 hours ago - Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing - PRNewsWire
- 7 hours ago - Novo Nordisk ends collaboration with Hims & Hers over weight loss drug sale - Reuters